Proteasome inhibition as a new strategy in cancer therapy and chemoprevention;Inhibicja aktywności proteasomu jako nowa strategia w terapii i chemioprewencji nowotworów

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 67, Issue , 2013, Pages 90-106

  Maliński, Michał ^a   Cichocki, Michał ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cancer chemotherapy; Chemoprevention; Induction of apoptosis; Proteasome inhibition

Indexed keywords

PROTEASOME INHIBITOR; UBIQUITIN;

ANIMAL; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; CHEMOPROPHYLAXIS; DRUG EFFECT; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CHEMOPREVENTION; HUMANS; NEOPLASMS; PROTEASOME INHIBITORS; SIGNAL TRANSDUCTION; UBIQUITIN;

MLCS; MLOWN;

EID: 84878639834     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1035963     Document Type: Article

References (104)

1. Ali R. E., Rattan S. I.: Curcumin's biphasic hormetic response on proteasome activity and heat-shock protein synthesis in human keratinocytes. Ann. N. Y. Acad. Sci., 2006;1067:394-399
2. An B., Goldfarb R. H., Siman R., Dou Q. P.: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ., 1998;5:1062-1075
3. Aoki S., Setiawan A., Yoshioka Y., Higuchi K., Fudetani R., Chen Z. S., Sumizawa T., Akiyama S., Kobayashi M.: Reversal of multidrug resistance in human carcinoma cell line by agosterols, marine spongean sterols. Tetrahedron, 1999;55:13965-13972
4. Aoki S., Yoshioka Y., Miyamoto Y., Higuchi K., Setiawan A., Murakami N., Chen Z. S., Sumizawa T., Akiyama S., Kobayashi M.: Agosterol A, a novel polyhydroxylated sterol acetate reversing multidrug resistance from a marine sponge of Spongia sp. Tetrahedron Lett., 1998;39:6303-6306
5. Archer C. R., Koomoa D. L., Mitsunaga E. M., Clerc J., Shimizu M., Kaiser M., Schellenberg B., Dudler R., Bachmann A. S.: Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma. Biochem. Pharmacol., 2010;80:170-178
6. Arlt A., Bauer I., Schafmayer C., Tepel J., Müerköster S. S., Brosch M., Röder C., Kalthoff H., Hampe J., Moyer M. P., Fölsch U. R., Schäfer H.: Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene, 2009;28:3983-3996
7. Asai A., Hasegawa A., Ochiai K., Yamashita Y., Mizukami T.: Belactosin A, a novel antitumor antibiotic acting on cyclin/CDK mediated cell cycle regulation, produced by Streptomyces sp. J. Antibiot., 2000;53:81-83
8. Asai A., Tsujita T., Sharma S. V., Yamashita Y., Akinaga S., Funakoshi M., Kobayashi H., Mizukami T.: A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay. Biochem. Pharmacol., 2004;67:227-234
9. Chauhan D., Singh A. V., Aujay M., Kirk C. J., Bandi M., Ciccarelli B., Raje N., Richardson P., Anderson K. C.: A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood, 2010;116:4906-4915
10. Chen D., Daniel K. G., Chen M. S., Kuhn D. J., Landis-Piwowar K. R., Dou Q. P.: Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem. Pharmacol., 2005;69:1421-1432
11. Cichocki M., Blumczyńska J., Baer-Dubowska W.: Naturally occurring phenolic acids inhibit 12-O-tetradecanoylphorbol-13-acetate induced NF-kappaB, iNOS and COX-2 activation in mouse epidermis. Toxicology, 2010;268:118-124
12. Ciechanover A.: The ubiquitin-proteasome proteolytic pathway. Cell, 1994;79:13-21
13. Clerc J., Groll M., Illich D. J., Bachmann A. S., Huber R., Schellenberg B., Dudler R., Kaiser M.: Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition. Proc. Natl. Acad. Sci. USA, 2009;106:6507-6512
14. Cole G. M., Teter B., Frautschy S. A.: Neuroprotective effects of curcumin. Adv. Exp. Med. Biol., 2007;595:197-212
15. Coleman C. S., Rocetes J. P., Park D. J., Wallick C. J., Warn-Cramer B. J., Michel K., Dudler R., Bachmann A. S.: Syringolin A, a new plant elicitor from the phytopathogenic bacterium Pseudomonas syringae pv. syringae, inhibits the proliferation of neuroblastoma and ovarian cancer cells and induces apoptosis. Cell Prolif, 2006;39:599-609
16. Craiu A., Gaczynska M., Akopian T., Gramm C. F, Fenteany G., Goldberg A. L., Rock K. L.: Lactacystin and clasto-lactacystin β-lactone modify multiple proteasome |3-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J. Biol. Chem., 1997;272:13437-13445
17. Crawford L. J., Walker B., Irvine A. E. Proteasome inhibitors in cancer therapy. J. Cell Commun. Signal., 2011;5:101-110
18. Cusack J. C. Jr., Liu R., Houston M., Abendroth K., Elliott P. J., Adams J., Baldwin A. S. Jr.: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res., 2001;61:3535-3540
19. Dai Y., Desano J., Tang W., Meng X., Meng Y., Burstein E., Lawrence T. S., Xu L.: Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PloS One, 2010;5:e14153
20. De Martino G. N., Slaughter C. A.: The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem., 1999;274:22123-22126
21. Dikshit P., Goswami A, Mishra A., Nukina N., Jana N. R.: Curcumin enhances the polyglutamine-expanded truncated N-terminal huntingtin-induced cell death by promoting proteasomal malfunction. Biochem. Biophys. Res. Commun., 2006;342:1323-1328
22. Dou Q. P., Landis-Piwowar K. R., Chen D., Huo C, Wan S. B., Chan T. H.: Green tea polyphenols as a natural tumour cell proteasome inhibitor. Inflammopharmacology, 2008;16:208-212
23. Fenteany G., Schreiber S. L.: Lactacystin, proteasome function, and cell fate. J. Biol. Chem., 1998;273:8545-8548
24. Fenteany G., Standaert R. F, Reichard G. A., Corey E. J., Schreiber S. L.: A P-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc. Natl. Acad. Sci. USA, 1994;91:3358-3362
25. Fujita T, Washio K., Takabatake D., Takahashi H., Yoshitomi S., Tsukuda K., Ishibe Y, Ogasawara Y, Doihara H., Shimizu N.: Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int. J. Cancer, 2005;117:670-682
26. Glickman M. H., Ciechanover A.: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev, 2002;82:373-428
27. Golden E. B., Lam PY, Kardosh A, Gaffney K. J., Cadenas E., Louie S. G., Petasis N. A, Chen T. C, Schönthal AH.: Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood, 2009;113:5927-5937
28. Groll M., Kim K. B., Kairies N., Huber R., Crews CM.: Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of α', β'-epoxyketone proteasome inhibitors. J. Am. Chem. Soc, 2000;122:1237-1238
29. Grzelakowska-Sztabert B.: Zależna od ubikwityny degradacja białek. Nagroda Nobla z chemii w 2004 roku. Kosmos - Problemy Nauk Biologicznych, 2005;54:133-148
30. Gulder T. A., Moore B. S.: Salinosporamide natural products: potent 20S proteasome inhibitors as promising cancer chemotherapeutics. Angew. Chem. Int. Ed. Engl., 2010;49:9346-9367
31. Hanada M., Sugawara K., Kaneta K., Toda S., Nishiyama Y., Tomita K., Yamamoto H., Konishi M., Oki T.: Epoxomicin, a new antitumor agent of microbial origin. J. Antibiot., 1992;45:1746-1752
32. Hanahan D., Weinberg R. A.: The hallmarks of cancer. Cell, 2000;100:57-70
33. Hatabu T., Hagiwara M., Taguchi N., Kiyozawa M., Suzuki M., Kano S., Sato K.: Plasmodium falciparum: The fungal metabolite gliotoxin inhibits proteasome proteolytic activity and exerts a plasmodicidal effect on P. falciparum. Exp. Parasitol., 2006;112:179-183
34. Irish J. M., Kotecha N., Nolan G. P.: Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat. Rev. Cancer, 2006;6:146-155
35. Jackson G., Einsele H., Moreau P., Miguel J. S.: Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat. Rev., 2005;31:591-602
36. Jana N. R., Dikshit P., Goswami A., Nukina N.: Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J. Biol. Chem., 2004;279:11680-11685
37. Kane R. C., Farrell A. T., Sridhara R., Pazdur R.: United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res., 2006;12:2955-2960
38. Kazi A., Daniel K. G., Smith D. M., Kumar N. B., Dou Q. P.: Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem. Pharmacol., 2003;66:965-976
39. Kisselev A. F., Callard A., Goldberg A. L.: Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J. Biol. Chem., 2006;281:8582-8590
40. Kitagawa S., Nabekura T., Kamiyama S.: Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J. Pharm. Pharmacol., 2004;56:1001-1005
41. Kitagawa S., Nabekura T., Nakamura Y., Takahashi T., Kashiwada Y.: Inhibition of P-glycoprotein function by tannic acid and pentagalloylglucose. J. Pharm. Pharmacol., 2007;59:965-969
42. Kroll M., Arenzana-Seisdedos F., Bachelerie F., Tomas D., Friguet B., Conconi M.: The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome. Chem. Biol., 1999;6:689-698
43. Krunic A., Vallat A., Mo S., Lantvit D. D., Swanson S. M., Orjala J.: Scytonemides A and B, cyclic peptides with 20S proteasome inhibitory activity from the cultured cyanobacterium Scytonema hofmanii. J. Nat. Prod., 2010;73:1927-1932
44. Kuhn D. J., Chen Q., Voorhees P. M., Strader J. S., Shenk K. D., Sun C. M., Demo S. D., Bennett M. K., Van Leeuwen F. W., Chanan-Khan A. A., Orlowski R. Z.: Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood, 2007;110:3281-3290
45. Landis-Piwowar K. R., Wan S. B., Wiegand R. A., Kuhn D. J., Chan T. H., Dou Q. P.: Methylation suppresses the proteasome-inhibitory function of green tea polyphenols. J. Cell. Physiol., 2007;213:252-260
46. Li W., Zhang X., Olumi A. F.: MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun. heterodimers and repressing c-FLIP (L). Cancer Res., 2007;67:2247-2255
47. Lin G., Li D., Chidawanyika T., Nathan C., Li H.: Fellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasome. Arch. Biochem. Biophys., 2010;501:214-220
48. Liu F. T., Agrawal S. G., Movasaghi Z., Wyatt P. B., Rehman I. U., Gribben J. G., Newland A. C., Jia L.: Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood, 2008;112:3835-3846
49. Löw P.: The role of ubiquitin-proteasome system in ageing. Gen. Comp. Endocrinol., 2011;172:39-43
50. Maity R., Sharma J., Jana N. R.: Capsaicin induces apoptosis through ubiquitin-proteasome system dysfunction. J. Cell. Biochem., 2010;109:933-942
51. Milacic V., Banerjee S., Landis-Piwowar K. R., Sarkar F. H., Majumdar A. P., Dou Q. P.: Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res., 2008;68:7283-7292
52. Mitsiades C. S., McMillin D., Kotoula V., Poulaki V., McMullan C., Negri J., Fanourakis G., Tseleni-Balafouta S., Ain K. B., Mitsiades N.: Antitumor effect of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J. Clin. Endocrinol. Metab., 2006;91:4013-4021
53. Mitsiades N., Mitsiades C. S., Poulaki V., Chauhan D., Fanourakis G., Gu X., Bailey C., Joseph M., Libermann T. A., Treon S. P., Munshi N. C., Richardson P. G., Hideshima T., Anderson K. C.: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA, 2002;99:14374-14379
54. Mitsiades N., Mitsiades C. S., Richardson P. G., Poulaki V., Tai Y. T., Chauhan D., Fanourakis G., Gu X., Bailey C., Joseph M., Libermann T. A., Schlossman R., Munshi N. C., Hideshima T., Anderson K. C.: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 2003;101:2377-2380
55. Molineaux S. M.: Molecular pathways: targeting proteasomal protein degradation in cancer. Clin. Cancer Res., 2012;18:15-20
56. Momose I., Sekizawa R., Hashizume H., Kinoshita N., Homma Y., Hamada M., Iinuma H., Takeuchi T.: Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. I. Taxonomy, isolation, physico-chemical properties and biological activities. J. Antibiot., 2001;54:997-1003
57. Momose I., Umezawa Y., Hirosawa S., Iinuma H., Ikeda D.: Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome. Bioorg. Med. Chem. Lett., 2005;15:1867-1871
58. Murata S., Takahama Y., Tanaka K.: Tymoproteasome: probable role in generating positively selecting peptides. Curr. Opin. Immunol., 2008;20:192-196
59. Myung J., Kim K. B., Crews C. M.: The ubiquitin-proteasome pathway and proteasome inhibitors. Med. Res. Rev., 2001;21:245-273
60. Nakamura H., Watanabe M., Ban H. S., Nabeyama W., Asai A.: Synthesis and biological evaluation of boron peptide analogues of Belactosin C as proteasome inhibitors. Bioorg. Med. Chem. Lett., 2009;19:3220-3224
61. Nam S., Smith D. M., Dou Q. P.: Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem., 2001;276:13322-13330
62. Nam S., Smith D. M., Dou Q. P.: Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and Bax expression, and induces G1 arrest and apoptosis. Cancer Epidemiol. Biomarkers Prev., 2001;10:1083-1088
63. Navon A., Ciechanover A.: The 26 S proteasome: from basic mechanisms to drug targeting. J. Biol. Chem., 2009;284:33713-33718
64. Nickeleit I., Zender S., Sasse F., Geffers R., Brandes G., Sörensen I., Steinmetz H., Kubicka S., Carlomagno T., Menche D., Gütgemann I., Buer J., Gossler A., Manns M. P., Kalesse M., Frank R., Malek N. P.: Argyrin A reveals a critical role for the tumor supressor protein p27kip1 in mediating antitumor activities in response to proteasome inhibition. Cancer Cell, 2008;14:23-35
65. Nitta T., Murata S., Sasaki K., Fujii H., Ripen A. M., Ishimaru N., Koyasu S., Tanaka K., Takahama Y.: Tymoproteasome shapes immunocompetent repertoire of CD8+ T cells. Immunity, 2010;32:29-40
66. O'Connor O. A., Stewart A. K., Vallone M., Molineaux C. J., Kunkel L. A., Gerecitano J. F., Orlowski R. Z.: A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin. Cancer Res., 2009;15:7085-7091
67. Orlowski R. Z.: The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ., 1999;6:303-313
68. Pahl H. L., Krauss B., Schulze-Osthoff K., Decker T., Traenckner E. B., Vogt M., Myers C., Parks T., Warring P., Muhlbacher A., Czernilofsky A. P., Bauerle P. A.: The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-κB. J. Exp. Med., 1996;183:1829-1840
69. Panischeva L. A., Kakpakova E. S., Rybalkina E. Y., Stavrovskaya A. A.: Influence of proteasome inhibitor bortezomib on the expression of multidrug resistance genes and Akt kinase activity. Biochemistry, 2011;76:1009-1016
70. Parlati F., Lee S. J., Aujay M., Suzuki E., Levitsky K., Lorens J. B., Micklem D. R., Ruurs P., Sylvain C., Lu Y., Shenk K. D., Bennett M. K.: Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood, 2009;114:3439-3447
71. Pasquini L. A., Besio Moreno M., Adamo A. M., Pasquini J. M., Soto E. F.: Lactacystin, a specific inhibitor of the proteasome, induces apoptosis and activates caspase-3 in cultured cerebellar granule cells. J. Neurosci. Res., 2000;59:601-611
72. Piva R., Ruggeri B., Williams M., Costa G., Tamagno I., Ferrero D., Giai V., Coscia M., Peola S., Massaia M., Pezzoni G., Allievi C., Pescalli N., Cassin M., Giovine S., Nicoli P., Feudis P., Strepponi I., Roato I., Ferracini R., Bussolati B., Camussi G., Jones-Bolin S., Hunter K., Zhao H., Neri A., Palumbo A., Berkers C., Ovaa H., Bernareggi A., Inghirami G.: CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood, 2008;111:2765-2775
73. Poulaki V., Mitsiades C. S., Kotoula V., Negri J., McMillin D., Miller J. W., Mitsiades N.: The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cells lines in vitro. Invest. Ophthalmol. Vis. Sci., 2007;48:4706-4719
74. Ravi R., Bedi A.: NF-kappaB in cancer - a friend turned foe. Drug Resist. Updat., 2004;7:53-67
75. Ravindran J., Prasad S., Aggarwal B. B.: Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J., 2009;11:495-510
76. Rechsteiner M., Realini C., Ustrell V.: The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem. J., 2000;345:1-15
77. Richardson P. G., Mitsiades C.: Bortezomib: proteasome inhibition as an effective anticancer therapy. Future Oncol., 2005;1:161-171
78. Richardson P. G., Mitsiades C., Hideshima T., Anderson K. C.: Proteasome inhibition in the treatment of cancer. Cell Cycle, 2005;4:290-296
79. Rock K. L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., Hwang D., Goldberg A. L.: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 1994;78:761-771
80. Ruschak A. M., Slassi M., Kay L. E., Schimmer A. D.: Novel proteasome inhibitors to overcome bortezomib resistance. J. Natl. Cancer Inst., 2011;103:1007-1017
81. Sanchez E., Li M., Steinberg J. A., Wang C., Shen J., Bonavida B., Li Z. W., Chen H., Berenson J. R.: The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br. J. Haematol., 2010;148:569-581
82. Sayers T. J., Murphy W. J.: Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol. Immunother., 2006;55:76-84
83. Shah S. A., Potter M. W., McDade T. P., Ricciardi R., Perugini R. A., Elliott P. J., Adams J., Callery M. P.: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem., 2001;82:110-122
84. Sliva D.: Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr. Cancer Drug Targets, 2004;4:327-336
85. Smith D. M., Wang Z., Kazi A., Li L. H., Chan T. H., Dou Q. P.: Synthetic analogs of green tea polyphenols as proteasome inhibitors. Mol. Med., 2002;8:382-392
86. Sorokin A. V., Kim E. R., Ovchinnikov L. P.: Proteasome system of protein degradation and processing. Biochemistry, 2009;74:1411-1442
87. Sun F., Anantharam V., Zhang D., Latchoumycandane C., Kanthasamy A., Kanthasamy A. G.: Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology, 2006;27:807-815
88. Tsukamoto S., Tatsuno M., Van Soest R. W., Yokosawa H., Ohta T.: New polyhydroxy sterols: proteasome inhibitors from a marine sponge Acanthodendrilla sp. J. Nat. Prod., 2003;66:1181-1185
89. Tsukamoto S., Yamanokuchi R., Yoshitomi M., Sato K., Ikeda T., Rotinsulu H., Mangindaan R. E., De Voogd N. J., Van Soest R. W., Yokosawa H.: Aaptamine, an alkaloid from the sponge Aaptos suberitoides, functions as a proteasome inhibitor. Bioorg. Med. Chem. Lett., 2010;20:3341-3343
90. Tsukamoto S., Yokosawa H.: Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy. Planta Med., 2010;76:1064-1074
91. Voorhees P. M., Dees E. C., O'Neil B., Orlowski R. Z.: The proteasome as a target for cancer therapy. Clin. Cancer Res., 2003;9:6316-6325
92. Wang R. E.: Targeting heat shock proteins 70/90 and proteasome for cancer therapy. Curr. Med. Chem., 2011;18:4250-4264
93. Watanabe T., Abe H., Momose I., Takahashi Y., Ikeda D., Akamatsu Y.: Structure-activity relationship of boronic acid derivatives of tyropeptin: proteasome inhibitors. Bioorg. Med. Chem. Lett., 2010;20:5839-5842
94. Wolf D. H., Hilt W.: The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochim. Biophys. Acta, 2004;1695:19-31
95. Wu W. K., Cho C. H., Lee C. W., Wu K., Fan D., Yu J., Sung J. J.: Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett., 2010;293:15-22
96. Wu W. K., Sakamoto K. M., Milani M., Aldana-Masankgay G., Fan D., Wu K., Lee C. W., Cho C. H., Yu J., Sung J. J.: Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy. Drug Resist. Updat., 2010;13:87-92
97. Wu W. K., Sung J. J., Wu Y. C., Li Z. J., Yu L., Cho C. H.: Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. Br. J. Pharmacol., 2008;154:632-638
98. Wu W. K., Sung J. J., Yu L., Cho C. H.: Proteasome inhibitor MG-132 lowers gastric adenocarcinoma TMK1 cell proliferation via bone morphogenetic protein signaling. Biochem. Biophys. Res. Commun., 2008;371:209-214
99. Xie Y.: Structure, assembly and homeostatic regulation of 26S proteasome. J. Mol. Cell Biol., 2010;2:308-317
100. Yang H., Chen D., Cui Q. C., Yuan X., Dou Q. P.: Celastrol, a triterpene extracted from the Chinese "Tunder of God Vine", is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res., 2006;66:4758-4765
101. Yang H., Shi G., Dou Q. P.: The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry". Mol. Pharmacol., 2007;71:426-437
102. Yew E. H., Cheung N. S., Choy M. S., Qi R. Z., Lee A. Y., Peng Z. F., Melendez A. J., Manikandan J., Koay E. S., Chiu L. L., Ng W. L., Whiteman M., Kandiah J., Halliwell B.: Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis. J. Neurochem., 2005;94:943-956
103. Zhang H. G., Wang J., Yang X., Hsu H. C., Mountz J. D.: Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene, 2004;23:2009-2015
104. Zhang Y., Shi Y., Li X., Du R., Luo G., Xia L., Du W., Chen B., Zhai H., Wu K., Fan D.: Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp. Cancer Biol. Ter., 2008;7:540-546